Developer docs
API playgroundTry for free, no card

Search company profiles

InDevR

Full company profile

uuid0000m3k

Namestring
InDevR
Legal namestring
InDevR, Inc.
Websiteurl
indevr.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

InDevR is a Boulder, Colorado-based life science tools company founded in 2003 that develops and commercializes microarray-based analytical solutions for vaccine and biotherapeutic characterization, potency testing, and quality control release. The company's core platform, VaxArray, is a multiplexed microarray immunoassay system that enables simultaneous quantification of more than 50 analytes per well across 24-well slides, producing results in under two hours versus the days required by traditional single-plex methods such as ELISA, SRID, flow cytometry, HPLC, and Luminex. InDevR's product portfolio includes ready-to-go reagent kits for seasonal and pandemic influenza (OmniFlu HA, OmniFlu HA/NA 96, pandemic H5/H7/H9 kits), a 23-valent pneumococcal serotyping kit developed with Bill & Melinda Gates Foundation support, a coronavirus serology kit, the 5'CapQ assay for rapid mRNA capping efficiency and integrity testing without extraction, and the CypherOne automated hemagglutination analyzer with 21 CFR Part 11 compliant software.

The company sells primarily to enterprise vaccine manufacturers (pharmaceutical and biotech), mRNA and cell/gene therapy developers, academic and government research labs, and contract research organizations, with named customers including CSL (Seqirus), Aldevron, QPS, Inventprise, Vaxess Technologies, Solaris Vaccines, and Colorado State University. InDevR monetizes through sales of reagent kits and instrumentation, supplemented by a higher-margin Expert Services line that delivers custom assay development. The go-to-market combines an enterprise field sales team with exclusive distribution partnerships: bioMérieux holds exclusive European rights for the VaxArray portfolio (since January 2023 with a board seat), and I&L Biosystems provides sales and support across Germany, Netherlands, France, and the UK. The company has historically relied heavily on non-dilutive funding, accumulating approximately $45M in government and foundation grants and contracts (including a $14.7M BARDA contract for FluChip-8G), alongside a $9M Series B in January 2023 from Adjuvant Capital and bioMérieux. In February 2026, SSI Diagnostica Group (Copenhagen) acquired InDevR, integrating it as a wholly owned affiliate within its Life Science Solutions portfolio.

Short descriptiontext

InDevR develops multiplexed microarray immunoassay kits and automated analyzers that enable vaccine manufacturers, mRNA developers, and research labs to perform rapid potency, identity, and quality control testing, selling through direct enterprise sales and exclusive European distribution partners bioMérieux and I&L Biosystems.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoulder, United States
HQ citystring
Boulder
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microarray immunoassays, vaccine quality control, multiplexed analytical solutions, mRNA capping assays, hemagglutination analyzers
Industry2 codes
PRIMARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Vaccine Analytical Instruments and Reagent Kits
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1VaxArray Product Kits
TypeHardware Sales
Description

Sale of ready-to-go reagent kits for the VaxArray platform including influenza kits (OmniFlu HA, OmniFlu HA/NA 96), pneumococcal kits, coronavirus kits, 5'CapQ assay, and custom multiplexed assay kits.

indevr.com
2CypherOne Instrument
TypeHardware Sales
Description

Sale of automated hemagglutination analyzer instrumentation.

indevr.com
3Expert Services
TypeProfessional Services
Description

Custom assay development and testing services. Expert Services team develops customized microarray assays for customers to address specific vaccine characterization needs, eliminating development bottlenecks.

indevr.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Pricing details2 tiers
1Microarray Scientist position
ModelOtherBilling cadenceAnnual
Notes

Base salary range: $75,000-90,000/year plus health benefits, SIMPLE IRA company match, and paid time off.

indevr.com
2Expert Services Laboratory Associate I position
ModelOtherBilling cadenceHourly
Notes

Base pay: $25.00-$32.00 per hour based on experience, skills, and market factors. Includes health benefits, 401(k) with company match, PTO, and paid holidays.

indevr.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1VaxArray
Description

Multiplexed microarray platform for vaccine potency testing and analytical characterization of vaccines and biotherapeutics

indevr.com
+4 more records
Core offering1 text field

InDevR develops and manufactures microarray-based multiplexed immunoassay kits and automated instruments under the VaxArray and CypherOne brands for vaccine potency testing, characterization, and quality control release. Its products are used by pharmaceutical and biotech vaccine manufacturers, mRNA and cell/gene therapy developers, CROs, and research labs to quantify multiple antigens or analytes in a single test with results in under 2 hours. The company also provides Expert Services for custom microarray assay development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Time to result: 2 hours vs. 48 hours for SRID (gold standard)
+3 more records
Product and service2 records
1VaxArray Platform
CategoryVaccine Analytical Instruments
Description

Multiplexed microarray immunoassay platform for vaccine potency testing, antigen/antibody quantification, serology, and quality control release testing across seasonal influenza, pneumococcal, mRNA, and other vaccine types. Used by vaccine manufacturers, mRNA and cell/gene therapy developers, CROs, and research labs.

2CypherOne System
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-04
Description

SSI Diagnostica Group, a Copenhagen-based company specializing in infectious disease testing solutions, acquired InDevR in February 2026. The acquisition strengthens SSI Diagnostica's leadership in pneumococcal vaccine QC testing while adding InDevR's expertise in influenza and mRNA vaccine QC testing to its Life Science portfolio.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2024-06-05
Description

Partnership to speed development of multiplexed assays for mRNA vaccines and cell and gene therapy applications. Sino Biological's catalog of high-quality antibodies, antigens, and reagents available for use on InDevR's VaxArray Platform.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2022-05-10
Description

PATH and partners developed monoclonal capture antibodies for VaxArray Pneumococcal Assay. Antibodies made available to industry through repository at MHRA site in South Mimms, UK (NIBSC standards).

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2017-09-18
Description

Exclusive worldwide license agreement for anti-neuraminidase monoclonal antibodies for rapid, subtype-specific quantification of neuraminidase in the multiplexed VaxArray system. Antibodies developed by Mount Sinai scientists.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2017-07-18
Description

Joint publication with FDA on Cypher One automated hemagglutination analyzer. Study 'Automated interpretation of influenza hemagglutination inhibition (HAI) assays' published in PLOS ONE showing 95% agreement between Cypher One and expert human readers.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2017-04-04
Description

Exclusive sales, marketing and customer support relationship for Cypher One and VaxArray product lines throughout Western Europe. I&L Biosystems has subsidiaries in Germany, Netherlands, France, and UK with native language support.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Provides bioprocess analytics and virus quantification tools used in vaccine manufacturing release, overlapping with InDevR's potency testing focus.

TypeBroad incumbent
Description

Major life sciences tools company whose Bio-Plex multiplex bead-based immunoassay platform directly competes with VaxArray in vaccine and biologics characterization workflows.

TypeDirect peer
Description

Developer of multiplex electrochemiluminescence immunoassay platforms widely used for vaccine potency and serology applications, offering overlapping functionality to InDevR's VaxArray.

TypeDirect peer
Description

Multiplex bead-based assay systems (MAGPIX, FLEXMAP 3D) used for vaccine and biologics analytics, now part of DiaSorin; competes with VaxArray's multiplexing approach.

TypeBroad incumbent
Description

Contract research and vaccine safety/potency testing services and products address the same vaccine manufacturer QC customers as InDevR.

TypeDirect peer
Description

Specializes in host cell protein and bioprocess impurity detection assays for vaccine and biologic manufacturing, sharing the biopharma QC customer base.

TypeBroad incumbent
Description

Supplies analytics and process solutions for biologic and vaccine manufacturing, including analytical instruments used in QC release workflows.

TypeEmerging player
Description

Provides immunoassay and quantification platforms for biologics development and manufacturing, offering parallel microanalytical capabilities to VaxArray.

TypeBroad incumbent
Description

Broad life sciences analytics portfolio (including Eurofins-acquired cell and gene therapy tools) covers vaccine and biotherapeutic QC workflows that overlap with InDevR's offerings.

TypeEmerging player
Description

Microplate readers and cell-based assay instruments used in vaccine potency and bioassay workflows, complementary to microarray-based VaxArray.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

InDevR

Vaccine Analytical Instruments and Reagent Kitsindevr.com

InDevR develops multiplexed microarray immunoassay kits and automated analyzers that enable vaccine manufacturers, mRNA developers, and research labs to perform rapid potency, identity, and quality control testing, selling through direct enterprise sales and exclusive European distribution partners bioMérieux and I&L Biosystems.

What InDevR does

InDevR is a Boulder, Colorado-based life science tools company founded in 2003 that develops and commercializes microarray-based analytical solutions for vaccine and biotherapeutic characterization, potency testing, and quality control release. The company's core platform, VaxArray, is a multiplexed microarray immunoassay system that enables simultaneous quantification of more than 50 analytes per well across 24-well slides, producing results in under two hours versus the days required by traditional single-plex methods such as ELISA, SRID, flow cytometry, HPLC, and Luminex. InDevR's product portfolio includes ready-to-go reagent kits for seasonal and pandemic influenza (OmniFlu HA, OmniFlu HA/NA 96, pandemic H5/H7/H9 kits), a 23-valent pneumococcal serotyping kit developed with Bill & Melinda Gates Foundation support, a coronavirus serology kit, the 5'CapQ assay for rapid mRNA capping efficiency and integrity testing without extraction, and the CypherOne automated hemagglutination analyzer with 21 CFR Part 11 compliant software.

The company sells primarily to enterprise vaccine manufacturers (pharmaceutical and biotech), mRNA and cell/gene therapy developers, academic and government research labs, and contract research organizations, with named customers including CSL (Seqirus), Aldevron, QPS, Inventprise, Vaxess Technologies, Solaris Vaccines, and Colorado State University. InDevR monetizes through sales of reagent kits and instrumentation, supplemented by a higher-margin Expert Services line that delivers custom assay development. The go-to-market combines an enterprise field sales team with exclusive distribution partnerships: bioMérieux holds exclusive European rights for the VaxArray portfolio (since January 2023 with a board seat), and I&L Biosystems provides sales and support across Germany, Netherlands, France, and the UK. The company has historically relied heavily on non-dilutive funding, accumulating approximately $45M in government and foundation grants and contracts (including a $14.7M BARDA contract for FluChip-8G), alongside a $9M Series B in January 2023 from Adjuvant Capital and bioMérieux. In February 2026, SSI Diagnostica Group (Copenhagen) acquired InDevR, integrating it as a wholly owned affiliate within its Life Science Solutions portfolio.

InDevR firmographics

Firmographics
Name
InDevR
Legal name
InDevR, Inc.
Website
https://indevr.com
Company type
Private
Founded year
2003
Operating status
Acquired
Headcount range
11–50 employees
Short description
InDevR develops multiplexed microarray immunoassay kits and automated analyzers that enable vaccine manufacturers, mRNA developers, and research labs to perform rapid potency, identity, and quality control testing, selling through direct enterprise sales and exclusive European distribution partners bioMérieux and I&L Biosystems.
Ownership category
akta.pro rank

InDevR industry classification

Industry
Product category
Vaccine Analytical Instruments and Reagent Kits
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)

Keywords

  • Microarray immunoassays
  • Vaccine quality control
  • Multiplexed analytical solutions
  • MRNA capping assays
  • Hemagglutination analyzers

Where InDevR is headquartered

Location

Headquarters

HQ city
Boulder
HQ country
United States
HQ region
North America

Offices1 record

Markets served

InDevR business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. VaxArray Product Kits: Sale of ready-to-go reagent kits for the VaxArray platform including influenza kits (OmniFlu HA, OmniFlu HA/NA 96), pneumococcal kits, coronavirus kits, 5'CapQ assay, and custom multiplexed assay kits.
  2. CypherOne Instrument: Sale of automated hemagglutination analyzer instrumentation.
  3. Expert Services: Custom assay development and testing services. Expert Services team develops customized microarray assays for customers to address specific vaccine characterization needs, eliminating development bottlenecks.

Pricing tiers

ModelBillingPrice
OtherAnnualMicroarray Scientist position
OtherHourlyExpert Services Laboratory Associate I position

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

InDevR product offering

Product offering

Core offering

InDevR develops and manufactures microarray-based multiplexed immunoassay kits and automated instruments under the VaxArray and CypherOne brands for vaccine potency testing, characterization, and quality control release. Its products are used by pharmaceutical and biotech vaccine manufacturers, mRNA and cell/gene therapy developers, CROs, and research labs to quantify multiple antigens or analytes in a single test with results in under 2 hours. The company also provides Expert Services for custom microarray assay development.

Differentiator

Problem solved

Functional benefit

Brands

  • VaxArray: Multiplexed microarray platform for vaccine potency testing and analytical characterization of vaccines and biotherapeutics
  • CypherOne
  • 5'CapQ
  • OmniFlu HA/NA
  • Expert Services

Products and services

  • VaxArray Platform Multiplexed microarray immunoassay platform for vaccine potency testing, antigen/antibody quantification, serology, and quality control release testing across seasonal influenza, pneumococcal, mRNA, and other vaccine types. Used by vaccine manufacturers, mRNA and cell/gene therapy developers, CROs, and research labs.
  • CypherOne System

Quantifiable outcome

  • Time to result: 2 hours vs. 48 hours for SRID (gold standard)
  • +3 more outcomes

Companies that use InDevR

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles4 records

InDevR technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

InDevR partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and strategic.

  • SSI Diagnostica GroupcoreStrategic or Co-development Partner · 4 February 2026SSI Diagnostica Group, a Copenhagen-based company specializing in infectious disease testing solutions, acquired InDevR in February 2026. The acquisition strengthens SSI Diagnostica's leadership in pneumococcal vaccine QC testing while adding InDevR's expertise in influenza and mRNA vaccine QC testing to its Life Science portfolio.
  • Sino BiologicalstrategicStrategic or Co-development Partner · 5 June 2024Partnership to speed development of multiplexed assays for mRNA vaccines and cell and gene therapy applications. Sino Biological's catalog of high-quality antibodies, antigens, and reagents available for use on InDevR's VaxArray Platform.
  • PATH (Program for Appropriate Technology in Health)strategicStrategic or Co-development Partner · 10 May 2022PATH and partners developed monoclonal capture antibodies for VaxArray Pneumococcal Assay. Antibodies made available to industry through repository at MHRA site in South Mimms, UK (NIBSC standards).
  • Mount Sinai (Icahn School of Medicine)coreTechnology or Integration · 18 September 2017Exclusive worldwide license agreement for anti-neuraminidase monoclonal antibodies for rapid, subtype-specific quantification of neuraminidase in the multiplexed VaxArray system. Antibodies developed by Mount Sinai scientists.
  • FDA (U.S. Food and Drug Administration)strategicStrategic or Co-development Partner · 18 July 2017Joint publication with FDA on Cypher One automated hemagglutination analyzer. Study 'Automated interpretation of influenza hemagglutination inhibition (HAI) assays' published in PLOS ONE showing 95% agreement between Cypher One and expert human readers.
  • I&L BiosystemscoreChannel Partner/ Reseller/ Distributor · 4 April 2017Exclusive sales, marketing and customer support relationship for Cypher One and VaxArray product lines throughout Western Europe. I&L Biosystems has subsidiaries in Germany, Netherlands, France, and UK with native language support.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

InDevR competitors and assessment

Company assessment

Broad incumbents

  • Sartorius: Provides bioprocess analytics and virus quantification tools used in vaccine manufacturing release, overlapping with InDevR's potency testing focus.
  • Bio-Rad Laboratories: Major life sciences tools company whose Bio-Plex multiplex bead-based immunoassay platform directly competes with VaxArray in vaccine and biologics characterization workflows.
  • Charles River Laboratories: Contract research and vaccine safety/potency testing services and products address the same vaccine manufacturer QC customers as InDevR.
  • Repligen: Supplies analytics and process solutions for biologic and vaccine manufacturing, including analytical instruments used in QC release workflows.
  • PerkinElmer: Broad life sciences analytics portfolio (including Eurofins-acquired cell and gene therapy tools) covers vaccine and biotherapeutic QC workflows that overlap with InDevR's offerings.

Direct peers

  • Meso Scale Diagnostics: Developer of multiplex electrochemiluminescence immunoassay platforms widely used for vaccine potency and serology applications, offering overlapping functionality to InDevR's VaxArray.
  • Luminex (DiaSorin): Multiplex bead-based assay systems (MAGPIX, FLEXMAP 3D) used for vaccine and biologics analytics, now part of DiaSorin; competes with VaxArray's multiplexing approach.
  • Cygnus Technologies: Specializes in host cell protein and bioprocess impurity detection assays for vaccine and biologic manufacturing, sharing the biopharma QC customer base.

Emerging players

  • Gyros Protein Technologies: Provides immunoassay and quantification platforms for biologics development and manufacturing, offering parallel microanalytical capabilities to VaxArray.
  • Molecular Devices: Microplate readers and cell-based assay instruments used in vaccine potency and bioassay workflows, complementary to microarray-based VaxArray.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

InDevR social profiles

Digital presence

InDevR financial estimates

Financial estimate

Revenue estimate

Valuation estimate

InDevR leadership team

Management profile

Number of profiles

Profiles8 records

InDevR funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

InDevR M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InDevR

What does InDevR do?

InDevR develops and manufactures microarray-based multiplexed immunoassay kits and automated instruments under the VaxArray and CypherOne brands for vaccine potency testing, characterization, and quality control release. Its products are used by pharmaceutical and biotech vaccine manufacturers, mRNA and cell/gene therapy developers, CROs, and research labs to quantify multiple antigens or analytes in a single test with results in under 2 hours. The company also provides Expert Services for custom microarray assay development.

Is InDevR a public or private company?

InDevR is a private company. It is classified as corporate owned and is currently acquired.

When was InDevR founded?

InDevR was founded in 2003. It employs 11 to 50 people.

Where is InDevR based?

InDevR is headquartered in Boulder, United States, in the North America region.

How does InDevR make money?

Three revenue lines are on record. VaxArray Product Kits are the primary driver. The others are cypherOne Instrument and expert Services.

Who are InDevR's main competitors?

Broad incumbents on record are Sartorius, Bio-Rad Laboratories, Charles River Laboratories, Repligen and PerkinElmer. Direct peers are Meso Scale Diagnostics, Luminex (DiaSorin) and Cygnus Technologies. Emerging players are Gyros Protein Technologies and Molecular Devices.

Does InDevR have an API?

No public API is recorded for InDevR.

What industry is InDevR in?

InDevR's product category is Vaccine Analytical Instruments and Reagent Kits. Its primary akta.pro industry code is HLAGADAH, Cell-Based & Potency Assays (Bioassays), with a secondary code of HLAAALAC, Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels). Its NAICS code is 325413 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GenengnewsMultiplexing Company InDevR Acquired by SSI Diagnostica GroupSSI Diagnostica Group has acquired InDevR, a company specializing in multiplexed analytical technologies for accelerated vaccine and biotherapeutic development and manufacturing. The acquisition enhances SSI Diagnostica's pneumococcal vaccine quality control testing capabilities and adds expertise in influenza and mRNA vaccine QC testing. InDevR's CEO stated that joining SSI Diagnostica will enable the combined company to deliver an integrated portfolio to global biopharma customers in vaccine and surveillance markets.IndevrSSI Diagnostica Group Acquires InDevRSSI Diagnostica Group, a Copenhagen-based company specializing in infectious disease testing solutions, has acquired InDevR, a Colorado-based provider of advanced multiplexing solutions for vaccine testing and quality control. The acquisition strengthens SSI Diagnostica Group's leadership in pneumococcal vaccine QC testing while adding expertise in influenza and mRNA vaccine quality control to its Life Science Solutions portfolio. The deal represents a continuation of SSI Diagnostica Group's M&A strategy to expand its global footprint and portfolio offerings in the infectious disease solutions market.YahooInDevR Launches Expert Services to Address Vaccine Development ChallengesInDevR Inc. launched Expert Services, offering tailored workflow solutions to address vaccine development bottlenecks. The service combines its VaxArray platform with custom-tailored services to accelerate analysis and validation of seasonal vaccines and novel biotherapeutics.SecSEC FORM DInDevR, Inc. filed a Form D with the SEC to announce an exempt securities offering under Rule 506(b), seeking to raise up to $9 million in equity. The filing indicates that approximately $6 million has been sold to three investors as of October 24, 2022, with the remainder remaining available for sale.Venture Capital Access OnlineInDevR Raises $9 Million in Series B Financing and Partners with bioMérieuxInDevR raised $9 million in Series B financing, with investments from Adjuvant Capital and bioMérieux, to support commercial expansion and development of its VaxArray platform. As part of the deal, bioMérieux became the exclusive distributor of the VaxArray portfolio in Europe and appointed a senior executive to InDevR's board.IndevrInDevR Raises $9 Million in Series B Financing and Partners with bioMérieuxInDevR, Inc. announced the closing of a $9 million Series B financing round, with investments from Adjuvant Capital and bioMérieux. Concurrently, bioMérieux secured exclusive distribution rights for InDevR's VaxArray platform in Europe and appointed a senior executive to InDevR's board. This partnership aims to expand commercial reach and support the development of new analytical reagent kits for vaccines and biotherapeutics.PR Newswire APACInDevR Launches VaxArray Polio Kit for Faster, Multiplexed Vaccine CharacterizationInDevR announced commercial availability of its VaxArray Polio D-antigen quantification kit for rapid polio vaccine testing. The kit is 10-20 times faster than traditional ELISA and can quantify all three poliovirus strains. It aims to reduce testing costs and support polio eradication efforts.PR NewswireInDevR Launches VaxArray Measles and Rubella Kit for Improved Vaccine Antigen CharacterizationInDevR, Inc. announced the commercial launch of its VaxArray Measles and Rubella antigen quantification kit, developed with funding from the Bill and Melinda Gates Foundation to accelerate vaccine manufacturing. The kit delivers antigen content analysis in 5 hours compared to the traditional 10–14-day tissue culture method, potentially reducing batch rejection rates and production costs per dose. InDevR collaborated with Hyderabad-based Biological E. Limited during development, with the kit now available as part of InDevR's broader VaxArray portfolio covering influenza and coronavirus solutions.